Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Multiple Myeloma 58Lymphoma, Large B-Cell, Diffuse 25Lymphoma, Follicular 23Lymphoma 18Leukemia, Lymphocytic, Chronic, B-Cell 17Recurrence 16Lymphoma, Non-Hodgkin 14Lymphoma, Mantle-Cell 14Lymphoma, B-Cell, Marginal Zone 12Lymphoma, B-Cell 10Neoplasms, Plasma Cell 9Waldenstrom Macroglobulinemia 6Hodgkin Disease 6Neoplasms 5Leukemia, Myeloid, Acute 5Burkitt Lymphoma 5Lymphoma, T-Cell 4Prostatic Neoplasms 3Ovarian Neoplasms 3Myelodysplastic Syndromes 3Lymphoma, T-Cell, Peripheral 3Lymphoma, Large-Cell, Anaplastic 3Leukemia 3Hematologic Neoplasms 3Sezary Syndrome 2Paraproteinemias 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Mycosis Fungoides 2Lymphoma, Large-Cell, Immunoblastic 2

Interventions

pembrolizumab 2Rituximab 2valomaciclovir 1threonic acid 1otelixizumab 1brincidofovir 1Valganciclovir 1Valacyclovir 1Tenofovir 1N-(2-amino-5-fluorobenzyl)-4-(N-(pyridine-3-acrylyl)aminomethyl)benzamide 1Matrix-M 1Magnesium Sulfate 1Lenalidomide 1Brentuximab Vedotin 1Bevacizumab 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Epstein-Barr Virus Infections × Lenalidomide × Clear all
NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

The Affiliated Hospital of Xuzhou Medical University

Phase 1/2 Not yet recruiting
30 enrolled

Infections, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡